J&J offers $134,000 grant to find the best start-up in South Korea

pharmafile | August 31, 2017 | News story | Research and Development J&J. pharma, Johnson & Johnson, drugs, life sciences, medicine, pharmaceutical, south korea 

Johnson & Johnson is doubling down its efforts to grow its business in East Asia by identifying and recruiting promising healthcare and biopharma start-up companies across South Korea as part of its venture acceleration programme. 

To this end, Johnson & Johnson Innovation, the US firm’s strategic venture division, has entered a partnership with the Seoul Metropolitan Government and the Korea Health Industry Development Institute (KHIDI) to launch the Seoul Innovation QuickFire Challenge, a programme to attract the cream of the country’s early-stage innovations.

J&J aims for the programme to lift the curtain on Korea’s unsung leaders in the development of health technologies for immunology, oncology, neuroscience, infectious diseases, bone and joint diseases and cardiovascular and metabolic diseases, as well as therapeutics and medical devices.

Winners of the challenge will be awarded a combined grant of up to 150,000 South Korean won ($134,000) and residency at the Seoul Bio Hub for two years, as well as mentorship from J&J Innovation and KHIDI for one year.

“We know that innovation can happen anywhere, and through the Seoul Innovation QuickFire Challenge Johnson & Johnson Innovation is here in Korea to identify great ideas and to accelerate game-changing innovation with key ecosystem players,” commented Dong Wu, Head of the Asia Pacific Innovation Center at J&J Innovation.

Matt Fellows

Related Content

J&J vaccine halted in US due to blood clots

The CDC and FDA have recommended a pause in the use of the Johnson & …

J & J to ship up to 400 million vaccines to Africa

Johnson & Johnson has reached an agreement to ship as many as 400 million doses …

Janssen’s multiple sclerosis treatment recommended by EMA

Janssen’s PONVORY therapy for the treatment of adults with relapsing forms of multiple sclerosis (MS) …

Latest content